Las Vegas, NV -- (SBWIRE) -- 12/24/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more. EquityObserver.com issues a special report on the following stocks: Gevo, Inc.(NASDAQ:GEVO),Atlantic Power Corp(NYSE:AT),Peregrine Pharmaceuticals(NASDAQ:PPHM),Athersys, Inc.(NASDAQ:ATHX)
Gevo, Inc.(NASDAQ:GEVO)managed to keep its gain at 2.36% on below-normal volume of 1.66Mshares. The stock settled at $1.30, after floating in a range of $1.28 - 1.34. Its latest price has reached market capitalization of $61.34M. Its 52-week range has been $1.12 - 2.75. Gevo, Inc., is a renewable chemicals and advanced biofuels company. The Company is focused on the development and commercialization of alternatives to petroleum-based products.
How Should Investors Trade GEVO Now?Don’t Miss out a Special Trend Analysis
Atlantic Power Corp(NYSE:AT)trading on a volume of 1.68Mshares, higher than its standard daily volume. Shares have been closed at $3.27. Over the last twelve months, the stock has lost-71.39% and faced a worst price of $3.06.Atlantic Power Corporation (Atlantic Power) owns and operates a fleet of power generation and infrastructure assets in the United States and Canada. The Company’s power generation projects.
Is AT a Solid Investment at These Levels?Read This Report for Details
Peregrine Pharmaceuticals(NASDAQ:PPHM)is up at $1.39 on above- normal volume of 1.89M shares during the last trading day. The stock has its 12-month range $1.11 - 2.78. Its Intraday range is $1.26 - 1.39.Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company developing monoclonal antibodies for the treatment and diagnosis of cancer.
How Should Investors Trade PPHM Now?Don’t Miss out a Special Trend Analysis
In the last trading day, Athersys, Inc.(NASDAQ:ATHX)is on high volume, trading at a volume of versus its average daily volume ratio 1.74M/1.06M shares. At $2.32, the stock has attained market capitalization of 163.62M.Athersys Inc. is a biopharmaceutical company engaged in the field of regenerative medicine.
Will Investors Buy ATHX After Reading This News?Just Go Here and Find Out
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/disclaimer-2/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)